Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | TSPO | P30536 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23823785 | 1.00 | PTGER4 (0.33) | PTGER4HCRTR1MMP12MMP13PRKDC | |
| SCHEMBL25459302 | 0.99 | PTGER4 (0.33) | PTGER4HCRTR1MMP12MMP13PRKDC | |
| SCHEMBL25459314 | 0.98 | ALK (0.32) | PTGER4HCRTR1TSPOKDM4EATM | |
| SCHEMBL25458753 | 0.97 | PTGER4 (0.34) | PTGER4HCRTR1MMP12MMP13PRKDC | |
| SCHEMBL25458795 | 0.97 | PTGER4 (0.34) | PTGER4HCRTR1MMP12MMP13PRKDC | |
| SCHEMBL25459220 | 0.97 | PTGER4 (0.31) | PTGER4HCRTR1TSPO | |
| SCHEMBL21666832 | 0.97 | ALK (0.32) | PTGER4PRKDCTSPOKDM4EATM | |
| SCHEMBL25458801 | 0.96 | PTGER4 (0.33) | PTGER4HCRTR1MMP12MMP13PRKDC | |
| SCHEMBL25459322 | 0.96 | PTGER4 (0.33) | PTGER4HCRTR1MMP12MMP13PRKDC | |
| SCHEMBL25459339 | 0.96 | PTGER4 (0.33) | PTGER4HCRTR1MMP12MMP13PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230247902-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, AND COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING DEVICE | LT MATERIALS CO., LTD. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230247902-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, AND COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING DEVICE | LT MATERIALS CO., LTD. (KR) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230247902-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, AND COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING DEVICE | CRY1, PPOX, ORC3 | PTGER4 2825/4885HCRTR1 1507/4885MMP12 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.